EUCTR2007-001724-12-IT进行中（未招募）不适用
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis - ND
Wyeth Pharmaceutricals France Wyeth Research Division0 个研究点目标入组 250 人开始时间: 2008年10月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. 18 years of age or older at time of consent. 2. Active, moderate to severe psoriasis defined by the following criteria: Clinically stable, plaque psoriasis involving 10% body surface area (BSA) or PASI 10. 3. In the opinion of the investigator, failure, intolerance, contraindication or not a candidate for the following: Methotrexate (MTX), cyclosporine, and psoralen plus ultraviolet A radiation (PUVA) therapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis. 2. Any rheumatologic disease such as rheumatoid arthritis, gout, systemic lupus erythematous, systemic vasculitis, scleroderma and polymyositis, or associated syndromes. 3. All biologics such as Anakinra (Kineret), infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), abatacept (Orencia), or rituximab (Rituxan) within 12 weeks of the baseline visit and through the end of the study (week 24).
研究者
相似试验
进行中（未招募）
1 期
A phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosismyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003415-98-HUIncyte Corporation212
进行中（未招募）
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaEUCTR2017-001903-60-DESanofi-aventis recherche & développement500
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, with Open-Label ExtensioBIPOLAR MANIAEUCTR2004-003781-14-ESJohnson and Johnson Pharmaceutical Research and Development, una división de Janssen-Cilag, S.A
进行中（未招募）
1 期
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)Extensive Stage Small Cell Lung Cancer (ED SCLC)EUCTR2016-003503-64-GBAbbvie Deutschland GmbH & Co. KG748
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsMedDRA version: 15.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's DiseaseEUCTR2011-004849-40-DEAbbVie Deutschland GmbH & Co. KG420